Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Lincoln Financial Q4 2025 Earnings Call - Capital rebuilt, annuities shift to spread-based mix to boost free cash flow
Lincoln closed 2025 with clear progress on the three priorities it laid out in 2023: a stronger capital foundation, an optimized operating model, and a shift toward more predictable, capital-efficient...
- Q4 adjusted operating income available to common stockholders was $434 million, or $2.21 per diluted share; full-year adjusted operating income exceeded $1.5 billion, up 23% vs 2024.
- Q4 adjusted operating income rose 31% year-over-year; this was the sixth consecutive quarter of year-over-year adjusted operating earnings growth.
- Free cash flow conversion improved to 45% in 2025, up from 35% in 2023, showing better ability to turn earnings into distributable cash.
- +14 more takeaways
Birkenstock First Quarter Fiscal 2026 Earnings Call - Strong Demand, FX and Tariffs Cut Reported Growth and Margins
Birkenstock posted a robust quarter, with revenue of EUR 402 million, up 18% in constant currency but only 11% reported as a result of a heavy FX headwind. Demand and brand momentum remain strong acro...
- Revenue EUR 402 million in Q1 fiscal 2026, up 18% in constant currency, 11% on a reported basis due to FX effects.
- FX created a 670 basis point headwind to revenue growth in Q1, with Q2 expected to face roughly 700 basis points of FX drag at current rates.
- B2B grew 24% in constant currency in Q1, DTC grew 12% in constant currency; B2B outperformance continued during holiday season.
- +17 more takeaways
Agios Pharmaceuticals Q4 2025 Earnings Call - ACTIVASE U.S. launch underway with 44 scripts in first five weeks and a 10-12 week conversion lag
Agios closed 2025 with a launch under its belt, $1.2 billion of cash, and a pipeline full of near-term catalysts. ACTIVASE received FDA approval in December and the U.S. launch is live, with 44 prescr...
- ACTIVASE approved by the FDA for alpha and beta thalassemia in December 2025; U.S. launch is underway.
- Management reported 44 prescriptions written by REMS-certified physicians in the first five weeks of the U.S. ACTIVASE launch, a strong early signal of demand.
- Average conversion from prescription to treatment initiation is expected to be 10-12 weeks, driven mainly by insurance prior authorization and a required baseline liver test.
- +16 more takeaways
Avient Corporation Q4 2025 Earnings Call - Margin Expansion and Cash Discipline Offset Flat Organic Sales; Defense and Healthcare Lead Growth
Avient closed 2025 with record adjusted EBITDA margins and tighter balance sheet, while organic sales were essentially flat. Management leaned on favorable mix, productivity and disciplined cash manag...
- Q4 2025: Adjusted EBITDA margins expanded 80 basis points versus prior year, and adjusted EPS grew 14% in the quarter per management.
- Full-year 2025: Record adjusted EBITDA margin of 16.7% and adjusted EBITDA of $545 million, a 3.5% increase year-over-year as reported.
- Organic sales in Q4 were down 0.8% and full-year 2025 organic sales were roughly flat; reported full-year sales were up 1.9% due to favorable FX.
- +12 more takeaways
Bitdeer Technologies Fourth Quarter 2025 Earnings Call - Pivoting to AI colocation while scaling self-mining and proprietary SealMiner production
Bitdeer closed Q4 2025 with headline growth, but not without friction. Revenue surged to $224.8 million, driven by rapid self-mining rollouts and SealMiner sales, and adjusted EBITDA was positive at $...
- Revenue jumped to $224.8 million in Q4 2025, up 226% year over year and 32.5% sequentially, driven primarily by higher self-mining hash rate and SealMiner sales.
- Adjusted EBITDA was positive $31.2 million for the quarter, a reversal from Q4 2024 negative figures, but down from $39.6 million in Q3 2025 due to higher energy and operating costs.
- Gross profit was $10.6 million and gross margin compressed to 4.7%, versus 24.1% in Q3 2025 and 7.4% in Q4 2024, largely because Bitcoin prices fell 13% quarter on quarter, electricity costs rose about 5% and depreciation surged.
- +16 more takeaways
Yatra Fiscal Q3 2026 Earnings Call - Corporate and international momentum offsets December IndiGo disruption, bookings and margins expand
Yatra reported broad-based gross booking growth and margin compression improvement despite a meaningful operational hit from airline schedule disruptions in early December. Management says gross booki...
- Gross bookings rose 22% year on year for air ticketing, reaching INR 16,931 million (about $188 million), management said.
- Revenue from operations grew 10% year on year to INR 2,577 million (about $29 million) for the quarter.
- Air passenger volumes increased roughly 13% to 1,491 thousand passengers, management alternatively referenced ~14% growth, indicating mid-teens passenger growth.
- +12 more takeaways
Trinity Industries Q4 2025 Earnings Call - Napier Park Restructuring Reveals $194M Gain, Wide Asset Upside
Trinity closed 2025 with a clean, if cautious, set of results. A strategic restructuring with Napier Park generated a $194 million non-cash gain and exposed a large market value premium on the company...
- Q4 EPS was $2.31, full-year 2025 EPS was $3.14, a 73% year-over-year increase and in line with prior guidance.
- Trinity recorded a $194 million non-cash gain from the December railcar partnership restructuring with Napier Park, after taking full ownership of the TRP 2021 fleet of ~6,235 cars.
- The company estimates its 101,000 wholly owned railcars (carrying value $6.3 billion) have a market value roughly 35% to 45% above carrying value, consistent with a long run 3% to 4% annual appreciation rate.
- +12 more takeaways
Gogoro Inc. Q4 2025 Earnings Call - Restructuring Drives Record Adjusted EBITDA, Gogoro Network Targets Profitability in 2026
Gogoro spent 2025 pruning complexity and cutting costs, and the numbers show the refocus worked. The company delivered a record adjusted EBITDA near $59.5-$59.9 million, operating cash flow of $31.1 m...
- Record adjusted EBITDA of roughly $59.5-$59.9 million for full year 2025, a clear result of the 2025 restructuring and cost cuts.
- Operating cash flow improved more than threefold to $31.1 million, signaling meaningful cash generation after the refocus.
- Full year revenue declined 9.4% to $281.5 million, driven by a 23.3% drop in hardware revenue to $132.5 million and softer Taiwan scooter volumes.
- +12 more takeaways
Utz Q4 2025 Earnings Call - Productivity-Fueled Margin Expansion Sets Up Free Cash Flow, Deleveraging and $50M Buyback
Utz closed 2025 with top-line resilience and a margin story that dominates the headlines. Branded salty snacks continued to grow for the eighth consecutive quarter, while aggressive productivity and a...
- Full-year 2025 organic net sales rose 2.4%, with branded salty organic sales up 4.7%, outpacing a retail category that was down 0.5%.
- Q4 2025 net sales were only up 0.4% as shipments lagged consumption late in the quarter due to retailer destocking; management says shipments normalized exiting the year and trends continued into 2026.
- Productivity delivered 7% of adjusted COGS in 2025, above the 6% target, funding marketing increases and contributing to substantial margin expansion.
- +12 more takeaways
British American Tobacco Full Year 2025 Earnings Call - Modern Oral Surge and U.S. Combustibles Drive Return to Growth, Setting Up Midterm Algorithm in 2026
BAT closed 2025 at the top end of guidance, led by a blistering Modern Oral performance and a reset U.S. combustibles franchise. Group revenue rose 2.1% on a constant currency basis, adjusted profit i...
- BAT delivered 2025 results at the top end of guidance, with group revenue up 2.1% and adjusted diluted EPS up 3.4% on a constant currency basis.
- The company added 4.7 million smokeless consumers in 2025, taking its total to 34.1 million, driven mainly by Modern Oral (VELO).
- Modern Oral revenue surged 48% globally, with VELO+ in the U.S. delivering over 300% growth and reaching positive category contribution within its first year.
- +11 more takeaways